Menu

Global Car-T Cell Therapy Market Size, By Targeted Antigen (CD 19, CD 20, GD 2, CD 22, CD 30, CD 33, HER1, HER2, MESO, EGFRVIII AND Others); By Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Leukemia, Multiple Myeloma, Pancreatic Cancer, Neuroblasta, Breast Cancer, Acute Myeloid Leukemia, Hepatocellular Carcinoma, Colorectal Cancer And Others); By Regional Analysis (North America - U.S, Canada, Other) (Asia-Pacific - India, Japan, China, Australia, Other) (Europe - UK, Russia, France, Brazil, Other) (Middle East and Africa) - Global Industry Insights, Trends and Forecast, 2017-2025

Report Format : PDF
Published Date : Dec-2018
Pages : 200
Report ID : VSR00416

Global Car-T Cell Therapy Market Size was valued nearly USD 296.5 million by 2017 and is estimated to reach up to USD xx.xx billion by 2025. According to latest study conducted by our analysts and industry experts, the global market is expected to grow at a CAGR of 45.6% during the forecast period, i.e. 2017-2025. Europe is expected to have significant growth over the forecast period, largely owing to the rising research and development on car-t cell therapies in the European region.

Global Market Growth Opportunities (Revenue, Growth) By 2017-2025

CAR-T Cell Therapy Market Size

Car-T cell therapy is a type of treatment in which, the T cells of a patient are modified so that they can fight cancer cells. It improves the body’s ability to detect and kill cancer cells.  Primarily, in this cancer treatment T-cells will accumulate, modified with CAR protein and is injected into the patient’s body. These cells then will act as an attacker on the cancer cells. This treatment is widely being adopted to treat various type of cancer includes pancreas cancer, colorectal cancer, breast cancer, and blood cancer.  The car-T cell therapy market size is anticipated to grow significantly over the projected period, owing to the growing cancer patients across the globe coupled with the approval of new therapies to cure the cancer.

Market Dynamics

The market is majorly driven by the rising incidence of numerous types of cancers including breast cancer, Leukemia, and others. For instance, in 2018, World Health Organization has estimated breast cancer cases recorded was 2.09 million cases, across the globe which would frost the global CAR-T cell therapy market share in the coming decade.  Furthermore, the incidence of Leukemia (acute Lymphocytic Leukemia) is rising, due to which  the U.S Food and Drug Administration has approved two Car-T cell therapies- Kymriah and Yescrata, used for the treatment of Leukemia which further accelerate the car-T cell therapy market.  Additionally, with the rising government initiatives in the healthcare industries and promoting research in cell therapy will accelerate the market growth. For instance, in 2016, the National Cancer Advisory Board has funded US$ 1.8 Bn, to foster the research process, to make more therapies available to patients with cancer.

However, various side effects are associated with the car-t cell therapy such as severe headaches, confusion, neurotoxity, and others. Moreover, it can also lead to cytokine release syndrome (CRS) and other neurological problems such as coma, hallucinations, and delirium, act as a restraining factor for the Car-T Cell Therapy market size growth.

Targeted Antigen Insights: CD 19 targeted antigen is anticipated to grow substantially over the CAGR over the forecast period owing to the rising clinical applications on the pronounced trial of the targeted CD19. This successful trial was funded by Kite Pharma for the treatment of B-cell lymphoma is further fueling the growth of Car-T cell therapy market share. The key pharmaceutical companies Kite Pharma, Novartis AG, Collectes S.A. and, others are involved in the manufacturing of CD 19 targeted antigen.

Application Insights: Leukemia disease particularly acute lymphocytic leukemia, chronic lymphocytic leukemia, and acute myeloid leukemia are perceived to grow at the significant CAGR over the forecast period followed by breast cancer. The growth is attributable due to the rising incidences of leukemia coupled with the increasing clinical trials to treat leukemia. For instance, in 2017, a clinical trial was initiated for the treatment of acute myeloid leukemia by using the combination of 8 different drugs including PF-04518600, avelumab, and azacitidine, glasdegib and avelumab and others. The trial is expected to accomplish by December 2024, which will further boost the Car-T Cell Therapy market size growth.

Regional Analysis

The global Car-T cell therapy market is divided into regions that are North America - U.S, Canada, Other) (Asia-Pacific -India, Japan, China, Australia, Other) (Europe - UK, Russia, France, Brazil, Other) (Middle East and Africa. Every region analysis details in sense of growth, revenue, volume, challenges, and opportunities with the regional and global key players. North America is anticipated to dominate the Car-T Cell Therapy market share owing to the enhancement of new therapies for cancer treatment. For instance, in 2017, the U.S. Food and Drug Administration (FDA) has approved Kymriah, a therapy to treat pediatric and young adult patients, who are diagnosed with acute lymphoblastic leukemia. This new therapy will further accelerate the market trend over the forecast year. Moreover, the growing cases of diseases in America such as breast cancer, Acute Lymphocytic Leukemia, and others will further foster the market growth. For instance, according to American Cancer Society, approximately 5,960 new incidences and 1,470 deaths by acute lymphocytic leukemia has been recorded, that further increases the opportunity for the Car-T cell therapy in US market.

Global CAR-T Cell Therapy Market Size, Share Analysis, By Region 2017

CAR-T Cell Therapy Market Share

Europe is expected to have significant growth over the forecast period, largely owing to the rising research and development on car-t cell therapies in the European region. For instance, in 2017, European Hematology and Oncology conducted a study on car-t cell therapy for Leukapheresis in the patients. This type of studies would increase the awareness amongst the population. Therefore, it would propel the Car-T Cell Therapy market size growth. Asia Pacific held the largest share of the global market in 2018 and will expand at the highest CAGR during the forecast years.

Global CAR-T Cell Therapy Market Study Objective

1. To forecast the market size of Car-T cell therapy market, along with describing and defining the market, in terms of volume and revenue.

2. Market analysis and forecast of Car-T cell therapy market on the basis of region, substrate and application or end-use industry.

3. To analyze and elaborate significant factors that will have major impact on the growth of Car-T cell therapy market, such as drivers, restraints, challenges and opportunities.

4. Regional analysis of Car-T cell therapy market, to induce market size of five global major regions, which include, Europe, North America, South America, Middle East & Africa and Asia Pacific.

5. Strategic analysis of micromarkets, in terms of individual prospects, opportunities, growth trends and their involvement in overall market.

6. To provide detailed analysis of competitive and strategic developments in the Car-T cell therapy market like new product launch, partnership & agreement, investment & expansion, and company merger & acquisitions.

7. Analysis of market opportunities for stakeholders, in order to provide a competitive landscape for global market players.

8. To profile major market players, and to analyze their market shares and essential competencies comprehensively.

Bottom-up and top-down are two main approaches that were taken into account to anticipate and validate the market size of Car-T cell therapy market, and to reach the anticipated market size of several dependent submarkets. The research and study involved massive utilization of secondary data sources, several directories, private and government websites, and authentic databases, to collect or gather market-oriented as well as technical information for the study of Car-T cell therapy market commercially.

Key Players Analysis

The key players operating in the market includes Celgene Corporation, Bellicum Pharmaceuticals, Pfizer, Inc. Kite Pharma, Inc., and several others. To stay competitive in the market, the players are involved in new product enhancement, and mergers & acquisitions. For instance, in 2018, Celgene Corporation, a developer of of Car-T and TCR (T cell receptor) announced to acquire June Therapeutics, Inc. to develop the transformative medicine for patients diagnosed with blood cancer. Moreover, strategic alliances are taking place to stay competitive in the global CAR-T cell therapy market. For instance, in April 2018, Pfizer, Inc. signed a deal with Allogene, for the development of an investigational CAR-T cell therapy for treating various types of blood cancer.

Global CAR-T Cell Therapy Market Study Report Offer You!

The global market study report gives an idea about market size, share, stock, equity, investment and total price analysis. Also, the report provides comprehensively industry insights with all major factors such as market credit, allocation, demand, distribution, market scope, key players, end user & applications, provisions, livestock, commodities and industry economics analysis, future growth & forecast. The global market report includes all depth data like pre-market emphasis, market survey, market investment, industry advice, portfolio, finance, access, trade, market exploration, industry review and market predication & projection to develop effective strategies for optimizing their market position.

Enquiry for Table of Content

Global Car-T Cell Therapy Market Size, By Targeted Antigen (CD 19, CD 20, GD 2, CD 22, CD 30, CD 33, HER1, HER2, MESO, EGFRVIII AND Others); By Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Leukemia, Multiple Myeloma, Pancreatic Cancer, Neuroblasta, Breast Cancer, Acute Myeloid Leukemia, Hepatocellular Carcinoma, Colorectal Cancer And Others); By Regional Analysis (North America - U.S, Canada, Other) (Asia-Pacific - India, Japan, China, Australia, Other) (Europe - UK, Russia, France, Brazil, Other) (Middle East and Africa) - Global Industry Insights, Trends and Forecast, 2017-2025

Enquiry for Methodology

Global Car-T Cell Therapy Market Size, By Targeted Antigen (CD 19, CD 20, GD 2, CD 22, CD 30, CD 33, HER1, HER2, MESO, EGFRVIII AND Others); By Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Leukemia, Multiple Myeloma, Pancreatic Cancer, Neuroblasta, Breast Cancer, Acute Myeloid Leukemia, Hepatocellular Carcinoma, Colorectal Cancer And Others); By Regional Analysis (North America - U.S, Canada, Other) (Asia-Pacific - India, Japan, China, Australia, Other) (Europe - UK, Russia, France, Brazil, Other) (Middle East and Africa) - Global Industry Insights, Trends and Forecast, 2017-2025

Single User: $4,999
Multi User: $6,999
Enterprice Licence: $8,999

Get 15% Discount

Why Choose Veracious Statistics Research ?

Save Your Time

Cost-Effective Services

Wide Range of Reports

World Class Market Research

100% Customer Satisfaction

24/7 Customer care Support

Any more questions?

Get in touch with us quickly and easily. We are happy to help!

Contact us

Sales Shaulova

Global Operations Manager +1-937-947-0908 Mon - Fri - 24/7/
Let's Talk - Online